Viking Therapeutics sets October 28 results date for Viking Therapeutics stock

Published on 10/25/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viking will report third-quarter results on October 28 after the close. A 4:30 p.m. ET call gives Viking Therapeutics stock its next test.

Upcoming results and financing

Viking announced its October 28, 2026 results date on October 21, 2026.
The September 28, 2026 financing covered 9,035,714 shares at USD 35.00 each.
Viking Therapeutics stock closed at EUR 22.25 on October 23, 2026 on Xetra.

VKTX, US92686J1060, Illustration mit AI erstellt.

Viking Therapeutics (ISIN US92686J1060) announced on October 21, 2026 that it will release third-quarter 2026 results after the market close on October 28, 2026, according to Viking Therapeutics. The company scheduled a conference call for 4:30 p.m. ET the same day, giving the clinical-stage biotechnology company a defined date for its next financial and pipeline update.

Three milestones since September

On September 28, 2026, Viking closed an offering that included 9,035,714 common shares priced at USD 35.00 each and USD 258.75 million of convertible senior notes due 2032, as reported by StockTitan.

On October 14, 2026, the company began its oral VK2735 Phase 3 SUNRISE program. Each of the two studies targets 560 adults and runs for 68 weeks, according to FinanzNachrichten.

On October 21, 2026, Viking set October 28, 2026 for its third-quarter release and 4:30 p.m. ET for the accompanying call, according to Viking Therapeutics.

What does the next report test?

The results will show how spending and financing have changed since the second quarter. For Q2 2026, Viking reported a loss of USD 128.02 million and a loss of USD 1.10 per share, versus a consensus loss of USD 1.21 per share, according to MarketBeat. The comparison gives the October 28 release two practical reference points: cash use and the pace of development spending.

Analyst target moves lower

Canaccord lowered its price target from USD 114.00 to USD 106.00 on October 20, 2026 while maintaining a Buy rating, as reported by Markets Insider. The target change reflects pricing assumptions for obesity treatments and leaves the results call as the next scheduled test of Viking's clinical and financial execution.

Dates set for the next update

October 28, 2026 is the date for Viking's third-quarter 2026 results, and October 28, 2026 at 4:30 p.m. ET is the date and time for its conference call, according to Viking Therapeutics.

Stock valuation before results

Viking Therapeutics stock closed at EUR 22.25 on Xetra on October 23, 2026. The last available euro quote stood at EUR 21.90 on Tradegate on October 23, 2026 at 9:34 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Viking Therapeutics stock.